11.06.2012 - The Innovative Medicines Initiative (IMI) has announced details on seven projects funded with a total budget of €215m.
The projects funded within the next five years include two coordinated by GlaxoSmithKline plc: model-based preclinical development of anti-tuberculosis (TB) drug combinations (PreDiCT-TB), which aim to make tuberculosis treatments more patient-friendly; and development of tools to predict immune response to biopharmaceuticals (ABIRISK). Sanofi is coordinating the DIRECT project to research patient stratification for personalised Type II diabetes treatments. Novartis AG and The University of Surrey (UK) are working on a project to develop biomarkers to test the safety of vaccines (BIOVACSAFE). A project coordinated by AstraZeneca plc is to develop tests for drug-induced liver injury (MIP-DILI); and one consortium coordinated by Roche seeks to develop research tools and diagnostics for autism spectrum disorder (EU-AIMS).
IMI also announced the launch of a Education and Training project called EUPATI, which shall create a European Patients’ Academy on Therapeutic Innovation. Its aim is to educate patients and the public about medicines development and empower patients to engage more effectively in the drug development process. The new projects mean that IMI is now supporting a total of 30 projects with a combined total cost of over €650m. IMI is a public-private partnership in health research and development. The European Union contributes €1 bn to the IMI research programme, which is matched by contributions worth at least another €1bn from the member companies of the European Federation of Pharmaceutical Industries and Associations (EFPIA).
29.08.2014 Just a week ago, Glaxosmithkline defused the WHO’s claim that an Ebola vaccine could be ready by 2015. Now, the British company’s own candidate vaccine is to be rushed to human trials with the help of funding from an international consortium.
24.08.2014 Germany's Morphosys is licensing a preclinical bi-specific antibody for the treatment of prostate cancer from Emergent Biosolutions. The US developer will rake in up to €138m for the commercialisation rights to the compound.
20.08.2014 Biopharmaceutical contract manufacturer Fujifilm Diosynth Biotechnologies is expanding its cell culture manufacturing capacity further with a new 2,000l single-use bioreactor at the company’s site in Billingham, UK.
08.08.2014 Boehringer Ingelheim is walking away from Swedish Orexo's prostaglandin inhibition project OX-MPI. Germany's largest researching pharmaceutical company had been responsible for the project's research and development since 2005.